A small cup-to-disc ratio is the strongest risk factor for NAION
Understanding the timeline helps you stay the course when progress feels slow
The STEP 1 Extension study found that patients who stopped semaglutide regained two-thirds of lost weight within one year without ongoing support
SURPASS-5 (NCT04039503) is a 40-week, multi-center, randomized, double-blind trial evaluating the efficacy and safety of tirzepatide compared to placebo in adults with inadequately controlled type 2 diabetes already being treated with insulin glargine, with or without metformin
Individual variation in requirements and absorption means no single protocol fits everyone
Perfect for dull or dry complexions, it delivers an instant moisture boost while improving tone, texture, and overall radianceanytime, anywhere